Keywords: Japan, Astellas, XenoPort, Gabapentin, Restless legs syndrome

Japanese filing of gabapentin enacarbil for RLS triggers $5 million milestone from Astellas to XenoPort

Article | 20 November 2009

Print This

Japanese drug major Astellas Pharma has filed a New Drug Application with the Pharmaceuticals and Medical Device Agency (PMDA) in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in